AC
ASMB icon

Apogem Capital’s Assembly Biosciences ASMB Stock Holding History

Apogem Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,742
Closed -$73K – 178
2021
Q3 		$73K Buy
1,742
+798
+85% +$33.4K 0.05% 185
2021
Q2 		$44K Buy
+944
New +$46.8K 0.03% 186

Other funds holding ASMB

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Apogem Capital's ASMB Position: Q4 2021 in Review

Apogem Capital sold out of Assembly Biosciences (ASMB) in Q4 2021, closing a stake of 1,742 shares — an estimated $73K sold.

Apogem Capital first reported a position in ASMB in Q2 2021 and held it in 2 quarters. The position peaked at $73K in Q3 2021. 62 funds tracked by Wall St. Rank hold ASMB as of Q4 2021.

  • Apogem Capital reported no remaining Assembly Biosciences position as of Q4 2021 after selling out during the quarter.
  • Apogem Capital sold 1,742 Assembly Biosciences shares in Q4 2021, an estimated $73K.
  • Apogem Capital first reported a position in Assembly Biosciences in Q2 2021 and held it in 2 quarters.
  • Apogem Capital's Assembly Biosciences position peaked at $73K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2021.

Based on Apogem Capital's 13F filing for Q4 2021, filed 14 Feb 2022.